Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Daiwa Names INNOVENT BIO (01801.HK) as Top Pick Alongside HENGRUI PHARMA (600276.SH) w/ TP Lifted to HKD112
Recommend 22 Positive 40 Negative 15 |
||||
|
||||
|
In 2025, the Chinese biopharmaceutical sector enjoyed a sweeping rally, Daiwa said in a research report. Looking ahead to 2026, the broker recommended adopting a more selective strategy and focusing on quality stocks. Regarding stock selection, Daiwa's top picks are INNOVENT BIO (01801.HK) and HENGRUI PHARMA (600276.SH). The target price for INNOVENT BIO has been raised from HKD95 to HKD112, while the target price for HENGRUI PHARMA remains at RMB80. AKESO (09926.HK) has been downgraded from Buy to Hold, yet its target price has jumped from HKD100 to HKD116. The Sell rating for CSPC PHARMA (01093.HK) is maintained alongside its target price of HKD6.6. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
